Business Wire

Eyenuk To Provide Artificial Intelligence (AI) Eye Screening to Thousands of Italians Through Collaboration With Ambrosian Ophthalmic Center in February

Share

Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that it is providing EyeArt® AI Eye Screening as part of the Month of Prevention of Diabetic Retinopathy (DR) and Maculopathy taking place throughout Italy in February. The collaboration between the Ambrosian Ophthalmic Center (CAMO), San Raffaele Hospital and Eyenuk™ is sponsored by the Italian Ministry of Health, the city of Milan and the Italian Ophthalmology Society.

During February, 30 centers across Italy will offer screening for DR using the EyeArt AI Eye Screening System, the most-extensively validated AI technology for autonomous detection of DR, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.

DR is a complication of diabetes and the main cause of vision impairment and blindness among working-age adults. It occurs when high blood sugar levels lead to damage in the blood vessels of the retina, the light-sensitive tissue at the back of the eye. Annual eye screening is recommended for people living with diabetes since DR can progress silently without any perceptible symptoms or vision deterioration.

“Early detection of DR is an important part of managing care for millions of people with diabetes, yet less than half of the people with diabetes see an eye doctor on an annual basis. AI Eye Screening can make early detection of DR more accessible, allowing patients to seek treatment and likely save their vision,” explains Dr. Lucio Buratto, scientific director of CAMO.

The EyeArt AI Eye Screening System is designed to make it possible for any physician to quickly and accurately detect referable DR patients in less than one minute during a diabetic patient’s regular exam. This helps remove the biggest obstacle to annual DR screening and diagnosis: patient compliance. With the EyeArt System, physicians can identify patients with vision-threatening DR in-clinic, in real time, so they can be immediately referred to a vision specialist for treatment to save their sight. The EyeArt System uses AI algorithms to autonomously analyze images of the eye taken with a retinal camera. This advancement can enable timely detection of vision-threatening DR by a nurse or non-specialist and eliminate the need for an eye care expert to carefully grade patient’s retinal images.

VIDEO: See How the EyeArt System Performs Eye Screening for Diabetic Retinopathy

“Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy,” says Kaushal Solanki, CEO of Eyenuk. “We are grateful for this opportunity to partner with these esteemed organizations in Italy to enable early detection of DR, thus advancing our mission with a critical step towards eliminating preventable blindness.”

For more information about the free AI Eye Screenings and the Month of Prevention of Diabetic Retinopathy and Maculopathy, please visit http://www.maculopatie.com/.

About Diabetic Retinopathy (DR)

DR is a complication of diabetes caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). It is a silently progressing disease. At first, DR progresses without any symptoms at all, but eventually it can cause blindness. The condition can develop in anyone with type 1 or type 2 diabetes.i It is estimated that one-third of all patients living with diabetes will develop the blinding disease,ii making it the leading cause of vision loss in working-age adults.iii

About Eyenuk Inc.

Eyenuk Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk’s first product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, validated in real world clinical studies with over 160,000 patient visits and over a million images. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.

EyeArt has CE marking and has been cleared for sales as a Class IIa medical device by EU and as a Class 2 medical device by Health Canada. In the U.S., the EyeArt® System is limited to investigational use only.

EyeArt® is a registered trademark of Eyenuk Inc.

www.eyenuk.com
media@eyenuk.com

_____________________________________
i https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms-causes/syc-20371611
ii Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. doi: 10.2337/dc11-1909
iii Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature reviewOphthalmic Res. 2012;47:171-188. doi: 10.1159/000329603

Contact information

Capwell Communications
Jensie Simkins
jensie@capwellcomm.com
949-999-3303

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Workiva Named Large Software Company of the Year by International Business Awards®21.10.2019 16:03:00 EESTPress release

Workiva (NYSE:WK), provider of the world’s leading connected reporting and compliance platform, has won a Gold Stevie® Award for Company of the Year in the large software company category in The 16th Annual International Business Awards®. The awards were presented at a gala ceremony in Vienna, Austria on October 19. “Workiva is honored to be recognized globally with a Gold Stevie Award,” said Marty Vanderploeg, CEO of Workiva. “We give our employees the freedom and resources they need – backed by our culture of collaboration and inclusion – to help our customers around the world build trust with connected reporting." The International Business Awards are the world’s premier business awards program. A record total of more than 4,000 nominations from organizations of various sizes and industries in 74 nations and territories were submitted this year for consideration in a wide range of categories. More than 250 executives worldwide served as Stevie Awards judges from May through August.

Mavenir Demonstrates Automated Deployment of Cloud-Native 5G Core at MWC LA21.10.2019 16:00:00 EESTPress release

Mobile World Congress: Mavenir, a US-based Network Software Provider, and the industry's only end-to-end cloud-native vendor for CSPs, announced today its 5G Core platform, which includes a comprehensive set of 5G core functions on a containerized cloud-native platform. The decomposition of functions into these modular units provides the operators the flexibility to scale them independently; scalability and flexibility that wasn’t possible with 4G EPC. Mavenir has invested heavily in developing the 5G Core solution from the ground-up on cloud-native principles that can still be retrofitted on EPCs. The solution encompasses all the major 5G core elements, such as AMF, SMF, UPF, NRF, UDSF, PCF, UDM, UDR, NSSF, AUSF, BSF, N3IWF, SCP, SEPP, and SMSF. All these functions are implemented as micro-services in containers. In addition, Mavenir is also building remaining 5G core functions, NEF, 5G-EIR, NWDAF etc. The Mavenir 5G Core also combines 4G EPC functionality and offers a ‘Converged Mobi

ResMed Introduces AirFit N30, World’s First Tube-Down Nasal Cradle CPAP Mask21.10.2019 16:00:00 EESTPress release

ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit N30, the world’s first tube-down nasal cradle CPAP mask with a front-facing tube – a brand-new option for sleep apnea treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005138/en/ ResMed AirFit N30, tube-down nasal cradle CPAP mask (Photo: Business Wire) ResMed’s lightest mask yet, AirFit N30 features an adjustable elastic headgear, plus a nasal cradle cushion that sits under the nasal bridge, eliminating soreness in that area. The mask’s curved cushion is designed to provide a secure seal regardless of how the wearer sleeps or moves. Together, these innovations help make starting and staying on CPAP therapy easier than ever for more of the 936 million people worldwide living with sleep apnea. “AirFit N30 is about ease of use, helping people ease into therapy and addressing the most common pain points for longtime users,” said Jim Hollingshead, president of R

STELARA® (ustekinumab) Data Demonstrate Long-term Efficacy and Safety Results in Adults With Moderately to Severely Active Ulcerative Colitis in Phase 3 Extension Trial21.10.2019 15:12:00 EESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of the Phase 3 UNIFI study, demonstrating the efficacy and safety of ustekinumab through two years of treatment in adults with moderately to severely active ulcerative colitis (UC). These data are being presented today as a late-breaking data presentation (LB01) at the 27th UEGW congress.1 These data include 399 participants who were in clinical response eight weeks after receiving a single intravenous (IV) induction dose of ustekinumab and who were then randomised to receive ustekinumab subcutaneous (SC) 90 mg injections every 12 weeks (q12w), ustekinumab SC 90 mg injections every 8 weeks (q8w), or placebo, and who were treated in the long-term extension.1 Results showed that the majority of patients were able to sustain remission through to week 92 as assessed by symptomatic remission. The percentage of patients receiving ustekinumab SC who were in symptomatic remi

H.I.G. Capital Acquires an Office Complex in Lyon21.10.2019 14:10:00 EESTPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global private equity investment firm with over $34 billion of equity capital under management, announced today that one of its affiliates has recently completed the acquisition of an office complex totaling approximately 29,000 sqm in Lyon, France’s second economic centre. The buildings are expected to be delivered in March 2021 and have already been 70% pre-let to an A rated French corporate tenant on a long-term basis. Terms were not disclosed. H.I.G. continues to add to its sizeable holdings of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Realty Partners Europe, commented: “Our focus in France is on high delivering quality assets with strong tenants that have the potential of becoming highly liquid institutional product as the result of the envisaged v

Rubicon Project Acquires RTK.io, A Leader in Open Source Header Bidding Solutions21.10.2019 13:00:00 EESTPress release

Rubicon Project (NYSE:RUBI), the global exchange for advertising, today announced the acquisition of RTK.io, a leading provider of tools and services that bring simplicity and control to header bidding for publishers. RTK’s solution is built on Prebid, the same open source framework as Demand Manager, the header bidding solution Rubicon Project launched in May 2019. RTK’s technology and team enable Rubicon Project to extend its Demand Manager product portfolio and client base. In the coming months, the company plans to integrate the two solutions to address the growing needs of publishers globally. Rubicon Project acquired RTK in an all-cash transaction for $11 million. “RTK shares our commitment to open source and our passion for serving publishers with powerful tools and incredible client service,” said Michael Barrett, President and CEO of Rubicon Project. “The company has a strong group of header bidding experts and Prebid developers that adds depth to our already great team. Toget

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom